Legend Biotech Corporation American Depositary Shares (LEGN) Stock Price

LEGNStock

$21.30−41.11%52W

Market Cap$4.14B

P/E—

PEG Ratio—

Div yield—

Beta0.56

LEGN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)2.87%

Price vs S&P 500 (4W)6.93%

VGM Score57.33

Book Value / Share (Quarterly)$2.71

P/TBV (Annual)5.75x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)106.41%

Cash Flow / Share (Quarterly)$-0.35

Price vs S&P 500 (YTD)-15.64%

Gross Margin (TTM)56.58%

Net Profit Margin (TTM)-7.20%

EPS (TTM)$-0.25

10-Day Avg Trading Volume2.56M

EPS Excl Extra (TTM)$-0.25

Revenue Growth (5Y)68.83%

EPS (Annual)$-0.81

ROI (Annual)-20.96%

Gross Margin (Annual)60.34%

Net Profit Margin (5Y Avg)-241.38%

Cash / Share (Quarterly)$2.56

Revenue Growth QoQ (YoY)51.93%

ROA (Last FY)-17.12%

Revenue Growth TTM (YoY)59.56%

EBITD / Share (TTM)$-0.03

ROE (5Y Avg)-40.14%

Operating Margin (TTM)-4.34%

Cash Flow / Share (Annual)$-0.35

P/B Ratio3.44x

P/B Ratio (Quarterly)4.54x

Net Income / Employee (Annual)$-102,300

EV / Revenue (TTM)3.02x

Net Interest Coverage (TTM)-0.88x

ROA (TTM)-5.39%

EPS Incl Extra (Annual)$-0.81

Current Ratio (Annual)1.96x

Quick Ratio (Quarterly)2.89x

3-Month Avg Trading Volume2.74M

52-Week Price Return-41.11%

Revenue / Employee (TTM)$438,400

Tangible BV / Share (Quarterly)$2.80

P/S Ratio (Annual)4.11x

Asset Turnover (Annual)0.59x

52-Week High$37.50

Operating Margin (5Y Avg)-242.40%

EPS Excl Extra (Annual)$-0.81

CapEx CAGR (5Y)-10.50%

Tangible BV CAGR (5Y)127.48%

26-Week Price Return14.11%

Quick Ratio (Annual)1.89x

13-Week Price Return-25.19%

Total Debt / Equity (Annual)0.41x

Current Ratio (Quarterly)3.04x

Enterprise Value$3.83B

Revenue / Share Growth (5Y)54.47%

Asset Turnover (TTM)0.75x

Book Value / Share Growth (5Y)116.84%

Revenue / Employee (Annual)$354,800

Inventory Turnover (Annual)14.60x

Pretax Margin (Annual)-27.47%

Cash / Share (Annual)$2.56

3-Month Return Std Dev109.23%

Net Income / Employee (TTM)$-31,600

ROE (Last FY)-29.62%

Net Interest Coverage (Annual)-1.22x

EPS Basic Excl Extra (Annual)$-0.81

Receivables Turnover (TTM)92.19x

Total Debt / Equity (Quarterly)0.23x

EPS Incl Extra (TTM)$-0.25

Receivables Turnover (Annual)106.14x

ROI (TTM)-6.43%

P/S Ratio (TTM)3.33x

Pretax Margin (5Y Avg)-241.58%

Revenue / Share (Annual)$2.79

Tangible BV / Share (Annual)$2.83

Forward P/E41.45x

Price vs S&P 500 (52W)-59.42%

Year-to-Date Return-3.68%

5-Day Price Return-4.47%

EPS Normalized (Annual)$-0.81

ROA (5Y Avg)-25.07%

Net Profit Margin (Annual)-28.85%

Month-to-Date Return12.88%

EBITD / Share (Annual)$-0.29

Operating Margin (Annual)-13.27%

LT Debt / Equity (Annual)0.29x

ROI (5Y Avg)-31.05%

LT Debt / Equity (Quarterly)0.17x

EPS Basic Excl Extra (TTM)$-0.25

P/TBV (Quarterly)6.34x

P/B Ratio (Annual)3.97x

Inventory Turnover (TTM)14.32x

Pretax Margin (TTM)-4.43%

Book Value / Share (Annual)$2.71

Price vs S&P 500 (13W)-27.98%

Beta0.56x

P/FCF (Annual)14.75x

Revenue / Share (TTM)$3.28

ROE (TTM)-8.70%

52-Week Low$16.24

vGradeC

gGradeA

mGradeD

vgmGradeC

LEGN Earnings Surprise History

Q2 25-0.68est. -0.23

Q3 25-0.22est. -0.18

Q4 25-0.16est. -0.19

Q2 260.32est. 0.28

LEGN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.17

4.18

4.09

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
LEGNLegend Biotech Corporation American Depositary Shares	C	A	D	$21.30
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Legend Biotech Corporation American Depositary Shares

Legend Biotech is a biopharmaceutical company developing cell therapies for cancer treatment. Its lead program, LCAR-B38M/JNJ-4528, is a CAR-T therapy in development for multiple myeloma. The company generates revenue through licensing and collaboration agreements, primarily with US partners.